title: [Chemotherapy of advanced colorectal cancers].
abstract: The medical treatment of advanced colon and rectum cancer is undergoing a revolution in the light of clinical studies defining the indications for conventional treatments as well as the development of new drugs. In this review, the authors discuss a number of practical questions raised every day by oncological teams. First-line chemotherapy must be administered to patients able to tolerate this treatment by the time of the diagnosis. The standard regiment of 5-FU and folinic acid (FUFOL) is gradually being superseded by more modern regimens, especially based on continuous 5-FU infusion, such as LV5-FU2. New drugs such as oxaliplatin, CPI-11 or tomudex are now available, and their place is currently under evaluation. These new drugs raise the question of the value of second-line chemotherapy, new commonly administered to patients with a persistently good general condition despite escape from first-line treatment. The various possible combinations of new drugs with 5-FU now confirm that current standards will be modified in the near future; while retaining the objective of improving survival, but also quality of life. The progress observed and expected will probably allow the development of more effective adjuvant treatment protocols.
authors.affiliation: Service de Médecine Interne-Oncologie, Hôpital Saint-Antoine, Paris.
authors.forename: C
authors.initials: C
authors.lastname: Louvet
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D019454:Chronotherapy; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D009367:Neoplasm Staging
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D005472:Fluorouracil